Status:
COMPLETED
Extension Study of GI198745 to Treat Benign Prostatic Hyperplasia
Lead Sponsor:
GlaxoSmithKline
Conditions:
Benign Prostatic Hyperplasia
Prostatic Hyperplasia
Eligibility:
MALE
50+ years
Phase:
PHASE2
Brief Summary
The primary objective is to assess the safety of GI198745 0.05mg, 0.5mg, 2.5mg once daily for 52 weeks.
Detailed Description
Upon completion of 24 weeks of GI198745 0.05 mg, 0.5 mg, 2.5 mg, or placebo therapy in study ARI20005, subjects are enrolled into an extension phase and are continued on the same therapy once daily fo...
Eligibility Criteria
Inclusion
- Has been receiving the investigational product for at least 20 weeks in the preceding dose finding study and the investigator or subinvestigator has confirmed the tolerability and has judged as appropriate to participate continuously in further 28 weeks treatment.
Exclusion
- Is withdrawn from the dose finding study.
- Has less than 75% compliance with the investigational product in the dose finding study at given the informed consent for the long-term extension study.
- Has a prostate cancer at giving informed consent for participating in the long-term extension study; or is suspected to have a prostate cancer in palpation, ultrasound imaging, biopsy, etc. at giving informed consent for participating in the long-term extension study.
- Has the post void residual volume \> 250 ml at starting the long-term extension study. (as measured by suprapubic ultrasound).
- Has chronic bacterial prostatitis or chronic urinary tract infections during the dose finding study
- Has acute urinary retention in the dose finding study.
- Has a history or current evidence of drug or alcohol abuse during the dose finding study
- Has been treated with any investigational product including post-marketing clinical trials during the dose finding study.
- Has myocardial infarction, coronary arterial bypass surgery, unstable angina, arrhythmia, congestive heart failure, cerebrovascular accident during the dose finding study.
- Has any concurrent disease or complication that, in the opinion of the investigator/sub-investigator, is difficult to evaluate efficacy of GI198745 in this study and that might poses additional risk to the patient.
- Is actively trying to procreate in the study period.
- Is unsuitable for this study, in the opinion of the investigator/sub-investigator.
Key Trial Info
Start Date :
August 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2005
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT00969072
Start Date
August 1 2003
End Date
February 1 2005
Last Update
September 13 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.